Spero Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Spero Therapeutics is Sath Shukla, benoemd in Aug2023, heeft een ambtstermijn van 1.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.02M, bestaande uit 25.9% salaris en 74.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.068% van de aandelen van het bedrijf, ter waarde € 41.57K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 10.5 jaar.

Belangrijke informatie

Sath Shukla

Algemeen directeur

US$2.0m

Totale compensatie

Percentage CEO-salaris	25.9%
Dienstverband CEO	1.3yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	10.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Sath Shukla's beloning veranderd ten opzichte van Spero Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$4m
Jun 30 2024	n/a	n/a	US$17m
Mar 31 2024	n/a	n/a	US$23m
Dec 31 2023	US$2m	US$524k	US$23m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$2m	US$478k	-US$46m
Sep 30 2022	n/a	n/a	-US$102m
Jun 30 2022	n/a	n/a	-US$113m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$2m	US$441k	-US$90m

Compensatie versus markt: De totale vergoeding ($USD 2.02M ) Sath } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.55K ).

Compensatie versus inkomsten: De vergoeding van Sath is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sath Shukla (51 yo)

1.3yrs

Tenure

US$2,024,647

Compensatie

Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ankit Mahadevia	Co-Founder & Chairman of the Board	11.2yrs	US$2.39m	0.43% € 260.1k
Satyavrat Shukla	President	1.3yrs	US$2.02m	0.068% € 41.6k
Timothy Keutzer	Chief Operating Officer	1.8yrs	US$1.44m	0.12% € 75.3k
Esther Rajavelu	CFO, Chief Business Officer & Treasurer	1.3yrs	geen gegevens	0.70% € 422.5k
James Brady	Chief Human Resource Officer	3yrs	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2HA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ankit Mahadevia	Co-Founder & Chairman of the Board	11.2yrs	US$2.39m	0.43% € 260.1k
Satyavrat Shukla	President	1.3yrs	US$2.02m	0.068% € 41.6k
Frank Thomas	Independent Director	7.3yrs	US$88.83k	0.028% € 16.7k
Milind Deshpande	Independent Director	10.8yrs	US$105.70k	0.058% € 35.0k
Eric Gordon	Scientific Advisors	10.5yrs	geen gegevens	geen gegevens
George Drusano	Clinical Advisor	10.5yrs	geen gegevens	geen gegevens
Steven Gilman	Scientific Advisor	no data	geen gegevens	geen gegevens
Patrick V. J. Vink	Lead Independent Director	9.2yrs	US$93.19k	0.028% € 16.7k
Gordon Archer	Clinical Advisor	10.5yrs	geen gegevens	geen gegevens
David Livermore	Scientific Advisor	no data	geen gegevens	geen gegevens
Paul Ambrose	Clinical Advisor	10.5yrs	geen gegevens	geen gegevens
Cynthia Smith	Independent Director	5.7yrs	US$73.20k	0.028% € 16.7k

10.5yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2HA zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.5 jaar).

Spero Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

Co-Founder & Chairman of the Board recently sold €81k worth of stock

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Recent updates

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.061 loss in 3Q 2023)

Investor sentiment improves as stock rises 17%

Spero Therapeutics, Inc. Announces SPR720 Phase 2a Interim Results

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.23 loss in 2Q 2023)

Spero Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.25 loss in 1Q 2023)

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

New major risk - Revenue and earnings growth

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.43 (vs US$1.24 loss in FY 2022)

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

Co-Founder & Chairman of the Board recently sold €81k worth of stock

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.061 loss per share (vs US$0.33 loss in 3Q 2022)

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.87 loss in 2Q 2022)

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.25 loss per share (vs US$1.01 loss in 1Q 2022)

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.24 loss per share (vs US$2.91 loss in FY 2021)

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.70 loss in 3Q 2021)

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.63 loss in 2Q 2021)

Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022

The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit

Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application

Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc

First quarter 2022 earnings released: US$1.01 loss per share (vs US$0.66 loss in 1Q 2021)

Spero Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

Insufficient new directors

Full year 2021 earnings released: US$2.91 loss per share (vs US$3.52 loss in FY 2020)

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206

Spero Therapeutics Receives Up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

Spero Therapeutics, Inc. Announces Lifting of FDA Clinical Trial Hold on SPR720

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem Hbr for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.86 loss in 3Q 2020)

Insufficient new directors

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.85 loss in 2Q 2020)

Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.

Spero Therapeutics, Inc. Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of Spr206

Spero Therapeutics, Inc. Wins Funding of $2.09 Million, with the Potential for Up to an Additional $21.3 Million over 5 Years, from the National Institute of Allergy and Infectious Diseases

First quarter 2021 earnings released: US$0.66 loss per share (vs US$1.22 loss in 1Q 2020)

Full year 2020 earnings released: US$3.52 loss per share (vs US$3.36 loss in FY 2019)

Revenue misses expectations

New 90-day high: €19.00

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

Spero Therapeutics Announces Issuance of Allowance for A U.S. Patent Covering Lead Candidate Tebipenem HBr